Popular Trials
PPAR Agonist
Saroglitazar for NAFLD in PCOS
This trial is testing a new medication called Saroglitazar Magnesium to see if it can help women with PCOS by reducing liver fat. The study will last several months and will measure changes in liver fat using MRI scans.
Dietary Supplement
Soluble Fibre Supplement for Fatty Liver Disease
This trial will investigate if a supplement can help reduce liver fat in children with fatty liver disease. Subjects will get pills, have bloodwork & diet monitored, and have liver fat measured via MRI.
Behavioral Intervention
LFSD for Preventing Fatty Liver Disease in Children
This trial tests if reducing sugar intake can prevent liver disease in overweight Hispanic children aged 6-9. Eating less sugar helps reduce liver fat, improving health and lowering disease risk.
Behavioral Intervention
Intermittent Fasting for Non-alcoholic Fatty Liver Disease
This trial is studying if time-restricted, intermittent fasting can help reduce liver fat in adults who are not obese. The idea is that fasting will make the body burn fat for energy instead of sugar, which might help decrease liver fat. Intermittent fasting has shown favorable effects on body weight and relevant indicators of liver health in several reports.
Dietary Supplement
Very Low Calorie Diet for Non-alcoholic Fatty Liver Disease
This trial is testing whether a very low-calorie diet can help improve non-alcoholic fatty liver disease (NAFLD) by reducing liver steatosis (fatty infiltration) and fibrosis (scarring). If successful, this could establish the diet as a clinically effective option for treating NAFLD, particularly for patients who are ineligible or don't have access to bariatric surgery.
Popular Filters
Trials for Non-alcoholic Fatty Liver Disease Patients
Procedure
BI 3006337 for Fatty Liver Disease
This trial is testing a new medicine called BI 3006337 in adults who are overweight or obese and have fatty liver disease. The goal is to find out how much of the medicine they can safely take. Participants receive regular injections and are closely monitored for any health issues.
Glucagon-like peptide-1 (GLP-1) receptor agonist
Efinopegdutide for Nonalcoholic Steatohepatitis (NASH)
This trial is testing a new medicine called efinopegdutide to see if it can help people with a liver disease called non-alcoholic steatohepatitis (NASH). Researchers want to find out if this medicine can reduce the symptoms of NASH without making liver scarring worse. They are also checking how safe the medicine is and how well people can tolerate it.
Behavioural Intervention
Low-Fructose Diet for Fatty Liver Disease in Youth
This trial will compare how two different diets (high vs low in high fructose corn syrup or HFCS) may affect how much fat gets deposited in the liver and whether or not a lower diet in HFCS can help decrease liver damage in adolescents with non-alcoholic fatty liver disease (NAFLD).
Trials for Metabolic Syndrome Patients
Procedure
BI 3006337 for Fatty Liver Disease
This trial is testing a new medicine called BI 3006337 in adults who are overweight or obese and have fatty liver disease. The goal is to find out how much of the medicine they can safely take. Participants receive regular injections and are closely monitored for any health issues.
Behavioural Intervention
Weight Loss for Obesity and Metabolic Syndrome
This trial is investigating how fat is stored in organs, and why this impacts some people's health more than others. The findings could lead to better treatments for diabetes and cardiovascular disease.
Metabolic Tests for Pediatric Non-alcoholic Fatty Liver Disease
This trial involves taking blood and liver tissue samples from children with NAFLD to understand the disease better. It focuses on this group because they are at higher risk of rapid disease progression. Researchers aim to find specific changes in the liver and blood that can help diagnose and understand NAFLD in children.
Potassium Channel Activator
Diazoxide for Non-alcoholic Fatty Liver Disease
This trial will compare 2 doses of diazoxide to placebo to see how they affect glucose and fat metabolism in people with IR-NAFLD. Participants will take 27 doses, have fasting blood tests and wear a glucose monitor for 14 days.
Trials With No Placebo
Behavioural Intervention
Low-Fructose Diet for Fatty Liver Disease in Youth
This trial will compare how two different diets (high vs low in high fructose corn syrup or HFCS) may affect how much fat gets deposited in the liver and whether or not a lower diet in HFCS can help decrease liver damage in adolescents with non-alcoholic fatty liver disease (NAFLD).
Behavioural Intervention
Weight Loss for Obesity and Metabolic Syndrome
This trial is investigating how fat is stored in organs, and why this impacts some people's health more than others. The findings could lead to better treatments for diabetes and cardiovascular disease.
Frequently Asked Questions
Introduction to nafld
What are the top hospitals conducting nafld research?
Amidst the rapidly growing concern over non-alcoholic fatty liver disease (NAFLD), several top hospitals have emerged as trailblazers in the field of clinical trials. In New york, Columbia University Irving Medical Center leads the way with two active NAFLD trials and a total of three completed studies dedicated to this condition. This institution made its mark by recording its first trial in 2023, demonstrating their commitment to advancing our understanding and treatment options for NAFLD. Similarly, Duke University Medical Center in Durham has been actively involved in tackling NAFLD since 2005 when they initiated their first trial. With two ongoing trials and an impressive track record of 27 previous investigations, Duke's efforts are helping shape the future management of this increasingly prevalent liver disease.
Meanwhile, at Mayo Clinic located in Rochester, Minnesota, research into NAFLD is also gaining momentum. Since commencing their initial trial in 2020, Mayo Clinic has currently undertaken two active trials while contributing to a cumulative total of three studies on this condition thus far. On the other side of Texas lies Worldwide Clinical Trials' Early Phase Services LLC based in San Antonio—a facility that may be smaller scale but nonetheless plays a crucial role within the landscape of NAFLD research. Having recorded its inaugural study on NALFD only recently in 2023 along with one current active trial underway; it proves that significant contributions can come from various institutions regardless size or location.
Lastly representing West Coast excellence is University of California, San Diego situated uniquely amidst picturesque La Jolla scenery where they have conducted eight all-time nafld clinical examinations so far while having one presently running investigation set up . Their journey began backin2009 when UCSD launched their maiden experiment focused solely on addressing Non-Alcoholic Fatty Liver Disease .
Together these leading hospitals demonstrate an unwavering dedication towards combating such ailments through innovative research approaches—each step toward unravelling secrets of NAFLD brings us closer to finding effective interventions and therapies for millions suffering worldwide.
Which are the best cities for nafld clinical trials?
When it comes to NAFLD clinical trials, several cities in the United States are at the forefront of research and innovation. San Antonio, Texas leads with 10 active trials investigating treatments like Resmetirom, Intervention/Drug, and Saroglitazar Magnesium 4 mg Tablet. Following closely behind are Chicago, Illinois and New york, New York with 5 ongoing studies each exploring interventions such as Efinopegdutide 4mg and Lisinopril. Additionally, Dallas, Texas and Tucson Arizona have 4 active trials focusing on Resmetirom, Efinopegdutide 4mg, and other potential therapies. These cities offer individuals affected by NAFLD access to cutting-edge clinical trials that may shape future treatment options for this complex condition.
Which are the top treatments for nafld being explored in clinical trials?
Clinical trials are paving the way for advancements in treating non-alcoholic fatty liver disease (NAFLD). Among the top contenders is semaglutide, currently being explored in two active trials. Since its first listing in 2016, it has become a subject of interest with a total of 11 NAFLD trials. Another promising treatment on the horizon is diazoxide oral suspension at a dosage of 1 mg per kg per dose, which is currently under investigation in one active trial and marks its debut on the clinical trial scene in 2023. These innovative approaches hold promise for improving outcomes and addressing this challenging condition.
What are the most recent clinical trials for nafld?
Important advancements are being made in the field of non-alcoholic fatty liver disease (NAFLD) through recent clinical trials. These studies aim to improve our understanding and treatment options for NAFLD, a condition characterized by excessive fat accumulation in the liver. Some of the most recent trials include evaluating the reduction toward euinsulinemia (RE) protocol, LY3885125, BI 3006337 dose group 4, diazoxide oral suspension, and bicalutamide for NAFLD patients. These trials focus on different approaches to address various aspects of the disease and have become available throughout August 2023. Through these ongoing investigations, we hope to uncover new strategies that will enhance patient outcomes and contribute to managing this prevalent health issue more effectively.
What nafld clinical trials were recently completed?
Numerous clinical trials focused on NAFLD have recently reached completion, demonstrating the commitment of researchers in addressing this prevalent liver condition. Among these trials are ALT-801 sponsored by Altimmune, Inc., which concluded in both March 2022 and September 2021; BIO89-100 sponsored by 89bio, Inc., completed in August 2021; Efinopegdutide 20 mg/mL sponsored by Merck Sharp & Dohme Corp., wrapped up in August 2021; AMG 609 sponsored by Amgen was finalized in May 2021; TERN-201 conducted under the sponsorship of Terns, Inc., achieved completion also in May 2021. Additionally, several other significant trials were successfully completed between November 2020 to December 2019 involving various pharmaceutical sponsors such as Oramed Ltd., National Institute of Allergy and Infectious Diseases (NIAID), Genentech Inc., Pfizer, NGM Biopharmaceuticals Inc., Novartis Pharmaceuticals, and Madrigal Pharmaceuticals Inc. These collective efforts underline the continuous pursuit for effective treatments for NAFLD.